Separase Inhibitor Sepin-1 Inhibits Foxm1 Expression and Breast Cancer Cell Growth

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Sepin-1, a separase inhibitor, shows anti-cancer properties, but its precise mechanism in breast cancer is unclear.
• Understanding Sepin-1's effects on cell growth and migration is crucial for developing targeted cancer therapies.

Purpose of the Study:

• To elucidate the molecular mechanisms underlying Sepin-1's inhibition of breast cancer cell growth, migration, and wound healing.
• To investigate the impact of Sepin-1 on apoptosis, cell cycle regulators, and signaling pathways.

Main Methods:

• In vitro studies on breast cancer cells treated with Sepin-1.
• Analysis of apoptosis markers (caspase 3/7 activation, Parp cleavage).
• Assessment of gene and protein expression, including FoxM1, Plk1, Cdk1, Aurora A, Lamin B1, and Raf kinases.

Main Results:

• Sepin-1 inhibited breast cancer cell growth, migration, and wound healing without inducing apoptosis.
• Sepin-1 treatment led to decreased expression of Forkhead box protein M1 (FoxM1) and its cell cycle-related target genes (Plk1, Cdk1, Aurora A, Lamin B1).
• Sepin-1 also downregulated the expression of Raf kinase family members (A-Raf, B-Raf, C-Raf), which are upstream regulators of FoxM1.

Conclusions:

• Sepin-1 inhibits breast cancer cell proliferation and migration primarily through growth inhibition, not apoptosis.
• The mechanism involves the downregulation of the Raf-Mek-Erk signaling pathway, leading to reduced FoxM1 expression and subsequent inhibition of cell cycle progression.
• These findings highlight Sepin-1 as a potential therapeutic agent for breast cancer by targeting key regulatory pathways.